Patents by Inventor Philip L. Nyce

Philip L. Nyce has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Processes and intermediates
    Patent number: 8293929
    Abstract: The invention relates to processes and compounds useful for producing modified aspartic acid derivatives, such as aspartic acid aldehyde moieties. Aspartic acid derivatives are useful for preparing caspase inhibitors and/or prodrugs thereof.
    Type: Grant
    Filed: October 12, 2010
    Date of Patent: October 23, 2012
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Gerald J. Tanoury, Minzhang Chen, Andrew D. Jones, Philip L. Nyce, Martin Trudeau, David J. Guerin, John R. Snoonian
  • Processes and Intermediates
    Publication number: 20110071298
    Abstract: The invention relates to processes and compounds useful for producing modified aspartic acid derivatives, such as aspartic acid aldehyde moieties. Aspartic acid derivatives are useful for preparing caspase inhibitors and/or prodrugs thereof.
    Type: Application
    Filed: October 12, 2010
    Publication date: March 24, 2011
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Gerald J. Tanoury, Minzhang Chen, Andrew D. Jones, Philip L. Nyce, Martin Trudeau, David J. Guerin, John R. Snoonian
  • Processes and intermediates
    Patent number: 7834200
    Abstract: The invention relates to processes and compounds useful for producing modified aspartic acid derivatives, such as aspartic acid aldehyde moieties. Aspartic acid derivatives are useful for preparing caspase inhibitors and/or prodrugs thereof.
    Type: Grant
    Filed: March 7, 2008
    Date of Patent: November 16, 2010
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Gerald J. Tanoury, Minzhang Chen, Andrew D. Jones, Philip L. Nyce, Martin Trudeau, David J. Guerin, John R. Snoonian
  • Processes and intermediates
    Publication number: 20090048429
    Abstract: The invention relates to processes and compounds useful for producing modified aspartic acid derivatives, such as aspartic acid aldehyde moieties. Aspartic acid derivatives are useful for preparing caspase inhibitors and/or prodrugs thereof.
    Type: Application
    Filed: March 7, 2008
    Publication date: February 19, 2009
    Inventors: Gerald J. Tanoury, Minzhang Chen, Andrew D. Jones, Philip L. Nyce, Martin Trudeau, David J. Guerin, John R. Snoonian
  • Processes and intermediates
    Patent number: 7381827
    Abstract: The invention relates to processes and compounds useful for producing modified aspartic acid derivatives, such as aspartic acid aldehyde moieties. Aspartic acid derivatives are useful for preparing caspase inhibitors and/or prodrugs thereof.
    Type: Grant
    Filed: March 11, 2005
    Date of Patent: June 3, 2008
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Gerald J. Tanoury, Minzhang Chen, Andrew D. Jones, Philip L. Nyce, Martin Trudeau, David J. Guerin, John R. Snoonian
  • Inhibitors of interleukin 1-? converting enzyme
    Patent number: 6974809
    Abstract: The present invention relates to novel classes of compounds which are inhibitors of interleukin-1? converting enzyme (“ICE”). This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting ICE activity and consequently, may be advantageously used as agents against interleukin-1-(“IL-1”), apoptosis-, interferon-? inducing factor-(IGIF), interferon-?-(“IFN-?”) mediated diseases, excess dietary alcohol intake diseases, or viral diseases, including inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, infectious diseases, and degenerative diseases. This invention also relates to methods for inhibiting ICE activity and decreasing IGIF production and IFN-? production and methods for treating interleukin-1, apoptosis- and interferon-?-mediated diseases using the compounds and compositions of this invention.
    Type: Grant
    Filed: April 25, 2003
    Date of Patent: December 13, 2005
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Julian M. C. Golec, David J. Lauffer, David J. Livingston, Michael D. Mullican, Mark A. Murcko, Philip L. Nyce, Andrea L. C. Robidoux, Marion W. Wannamaker
  • Inhibitors of interleukin 1-beta converting enzyme
    Publication number: 20040048855
    Abstract: The present invention relates to novel classes of compounds which are inhibitors of interleukin-1&bgr; converting enzyme (“ICE”). This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting ICE activity and consequently, may be advantageously used as agents against interleukin-1-(“IL-1”), apoptosis-, interferon-&ggr; inducing factor-(IGIF), interferon-&ggr;-(“IFN-&ggr;”) mediated diseases, excess dietary alcohol intake diseases, or viral diseases, including inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, infectious diseases, and degenerative diseases.
    Type: Application
    Filed: April 25, 2003
    Publication date: March 11, 2004
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Julian M .C. Golec, David J. Lauffer, David J. Livingston, Michael D. Mullican, Mark A. Murcko, Philip L. Nyce, Andrea L.C. Robidoux, Marion W. Wannamaker
  • Inhibitors of interleukin-1&bgr; converting enzyme
    Patent number: 6573259
    Abstract: The present invention relates to novel classes of compounds which are inhibitors of interleukin-1&bgr; converting enzyme (“ICE”). This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting ICE activity and consequently, may be advantageously used as agents against interleukin-1-(“IL-1”), apoptosis-, interferon-&ggr; inducing factor-(IGIF), interferon-&ggr;-(“IFN-&ggr;”) mediated diseases, excess dietary alcohol intake diseases, or viral diseases, including inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, infectious diseases, and degenerative diseases.
    Type: Grant
    Filed: October 23, 2001
    Date of Patent: June 3, 2003
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Julian M. C. Golec, David J. Lauffer, David J. Livingston, Michael D. Mullican, Mark A. Murcko, Philip L. Nyce, Andrea L. C. Robidoux, Marion W. Wannamaker
  • Inhibitors of interleukin-1beta converting enzyme
    Publication number: 20030069228
    Abstract: The present invention relates to novel classes of compounds which are inhibitors of interleukin-1&bgr; converting enzyme (“ICE”). This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting ICE activity and consequently, may be advantageously used as agents against interleukin-1-(“IL-1”), apoptosis-, interferon-&ggr; inducing factor-(IGIF), interferon-&ggr;- (“IFN-&ggr;”) mediated diseases, excess dietary alcohol intake diseases, or viral diseases, including inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, infectious diseases, and degenerative diseases.
    Type: Application
    Filed: October 23, 2001
    Publication date: April 10, 2003
    Inventors: Julian M.C. Golec, David J. Lauffer, David J. Livingston, Michael D. Mullican, Mark A. Murcko, Philip L. Nyce, Andrea L.C. Robidoux, Marion W. Wannamaker
  • Inhibitors of interleukin-1&bgr; converting enzyme
    Patent number: 6350741
    Abstract: The present invention relates to novel classes of compounds which are inhibitors of interleukin-1&bgr; converting enzyme (“ICE”). This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting ICE activity and consequently, may be advantageously used as agents against interleukin-1-(“IL-1”), apoptosis-, interferon-&ggr; inducing factor-(IGIF), or interferon-&ggr;-(“IFN-&ggr;”) mediated diseases, including inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, infectious diseases, and degenerative diseases. This invention also relates to methods for inhibiting ICE activity and decreasing IGIF production and IFN-&ggr; production and methods for treating interleukin-1, apoptosis- and interferon-&ggr;-mediated diseases using the compounds and compositions of this invention.
    Type: Grant
    Filed: June 4, 1999
    Date of Patent: February 26, 2002
    Assignee: Vertex Pharmaceutical, Inc.
    Inventors: Julian M. C. Golec, David J. Lauffer, David J. Livingston, Michael D. Mullican, Philip L. Nyce, Andrea L. C. Robidoux, Marion W. Wannamaker
  • Inhibitors of interleukin-1&bgr; converting enzyme
    Patent number: 6329365
    Abstract: The present invention relates to novel classes of compounds which are inhibitors of interleukin-1&bgr; converting enzyme (“ICE”). This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting ICE activity and consequently, may be advantageously used as agents against interleukin-1-(“IL-1”), apoptosis-, interferon-&ggr; inducing factor-(IGIF), interferon-&ggr;-(“IFN-&ggr;”) mediated diseases, excess dietary alcohol intake diseases, or viral diseases, including inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, infectious diseases, and degenerative diseases.
    Type: Grant
    Filed: June 4, 1999
    Date of Patent: December 11, 2001
    Assignee: Vertex Pharmaceuticals, Inc.
    Inventors: Julian M. C. Golec, David J. Lauffer, David J. Livingston, Michael D. Mullican, Mark A. Murcko, Philip L. Nyce, Andrea L. C. Robidoux, Marion W. Wannamaker
  • Heterocycle substituted propenoic acid derivatives and pharmaceutical compositions thereof
    Patent number: 5563157
    Abstract: The present invention is new 3-(heterocyclic)-propenoic acid derivatives and pharmaceutical compositions thereof. These new 3-(heterocyclic)-propenoic acid derivatives are useful as NMDA antagonist.
    Type: Grant
    Filed: October 31, 1994
    Date of Patent: October 8, 1996
    Assignee: Hoechst Marion Roussel Inc.
    Inventors: Boyd L. Harrison, Philip L. Nyce, Robert A. Farr
  • 3-(indol-3-yl)-propenoic acid derivatives and pharmaceutical compositions thereof
    Patent number: 5519048
    Abstract: The present invention is new 3-(indol-3-yl)-propenoic acid derivatives and pharmaceutical compositions thereof. These new 3-indolyl-3-yl-prpopenoic acid derivatives are useful as NMDA antagonist.
    Type: Grant
    Filed: May 16, 1995
    Date of Patent: May 21, 1996
    Assignee: Merrell Pharmaceuticals Inc.
    Inventors: Francesco G. Salituro, Bruce M. Baron, Boyd L. Harrison, Philip L. Nyce